Table 3.

Adverse events.

	Any grade			Grade ≥3
	CCRT alone (n=58)	CCRT+ICI (n=43)	P	CCRT alone (n=58)	CCRT+ICI (n=43)	P
Hematological events
Leukopenia			0.039			0.990
no	4 (6.9%)	10 (23.3%)		35 (60.3%)	26 (60.5%)
yes	54 (93.1%)	33 (76.7%)		23 (39.7%)	17 (39.5%)
Neutropenia			0.213			0.843
no	15 (25.9%)	17 (39.5%)		44 (75.9%)	31 (72.1%)
yes	43 (74.1%)	26 (60.5%)		14 (24.1%)	12 (27.9%)
Anemia			0.983			0.870
no	8 (13.8%)	5 (11.6%)		53 (91.4%)	38 (88.4%)
yes	50 (86.2%)	38 (88.4%)		5 (8.6%)	5 (11.6%)
Thrombocytopenia			0.150			0.999
no	34 (58.6%)	32 (74.4%)		53 (91.4%)	40 (93.0%)
yes	24 (41.4%)	11 (25.6%)		5 (8.6%)	3 (7.0%)
Non-hematological events
Liver dysfunction			0.999			0.999
no	53 (91.4%)	39 (90.7%)		57 (98.3%)	43 (100.0%)
yes	5 (8.6%)	4 (9.3%)		1 (1.7%)	0 (0.0%)
Creatine kinase increased			0.243			0.243
no	58 (100.0%)	42 (97.7%)		58 (100.0%)	42 (97.7%)
yes	0 (0.0%)	1 (2.3%)		0 (0.0%)	1 (2.3%)
Hypothyroidism			0.349			0.880
no	58 (100.0%)	41 (95.3%)		58 (100.0%)	42 (97.7%)
yes	0 (0.0%)	2 (4.7%)		0 (0.0%)	1 (2.3%)
Nausea			0.182			0.998
no	41 (70.7%)	24 (55.8%)		57 (98.3%)	43 (100.0%)
yes	17 (29.3%)	19 (44.2%)		1 (1.7%)	0 (0.0%)
Vomiting			0.470			0.612
no	47 (81.0%)	38 (88.4%)		56 (96.6%)	43 (100.0%)
yes	11 (19.0%)	5 (11.6%)		2 (3.4%)	0 (0.0%)
Diarrhea			0.998			0.998
no	57 (98.3%)	42 (97.7%)		57 (98.3%)	43 (100.0%)
yes	1 (1.7%)	1 (2.3%)		1 (1.7%)	0 (0.0%)
Dermatitis			0.349			0.999
no	58 (100.0%)	41 (95.3%)		58 (100.0%)	43 (100.0%)
yes	0 (0.0%)	2 (4.7%)		0 (0.0%)	0 (0.0%)
Fistula			0.999			0.999
no	56 (96.6%)	41 (95.3%)		56 (96.6%)	41 (95.3%)
yes	2 (3.4%)	2 (4.7%)		2 (3.4%)	2 (4.7%)
Pneumonitis			0.008			0.421
no	37 (63.8%)	15 (34.9%)		56 (96.6%)	39 (90.7%)
yes	21 (36.2%)	28 (65.1%)		2 (3.4%)	4 (9.3%)

CCRT, concurrent chemoradiotherapy; ICI, immune checkpoint inhibitors.